Recruiting
Phase 3

Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Sponsor:

RayzeBio, Inc.

Code:

NCT05477576

Conditions

GEP-NET

Gastroenteropancreatic Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor Disease

Neuroendocrine Tumors

Carcinoid

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RYZ101

Everolimus

Sunitinib

Octreotide

Lanreotide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information